Profits Over Patients: Merck's Oncology Spin-off Reveals Healthcare's True Priorities
Merck's decision to cleave its oncology portfolio into a distinct entity, separating it from its non-cancer drug operations, reflects a relentless drive for market optimization. This move, framed as enhancing focus and shareholder value, is not an isolated incident. It is another chapter in a long history where the pursuit of astronomical profits has reshaped healthcare landscapes, directing
investment towards the most lucrative areas while often neglecting less profitable, though equally vital, medical needs. The pharmaceutical industry, since its post-World War II boom, has consistently demonstrated this trend, consolidating power and resources. This corporate maneuver parallels the 1960s, when the American Medical Association actively lobbied against universal healthcare, fearing
government intervention would curb private pharmaceutical and medical device profits. Now, instead of direct lobbying against public programs, we see internal restructuring designed to carve out higher revenue streams from specialized, high-cost treatments. Oncology drugs, for instance, command some of the highest prices in the pharmaceutical market, with treatments frequently exceeding $100,000
per year for a single patient. This financial incentive inevitably skews research and development budgets, drawing capital away from areas like neglected tropical diseases or antibiotic resistance, which offer lower returns on investment. The impact extends globally. In 2022, only 53% of the world's population had access to essential health services, a disparity exacerbated by profit-driven drug